A center for developing active ingredient delivery systems will appear at the Russky Innovative Science and Technology Center (ISTC) in Vladivostok. One of its first products will be liposomal vitamin D with increased bioavailability.
“One of our projects as residents of the ISTC is the launch of our own AI platform for the accelerated design and in vitro testing of liposomal delivery systems for biologically active substances, for example, vitamin D. Such solutions make it possible to significantly increase bioavailability — potentially up to 90% compared to 30-40% for traditional forms,” explained Lyudmila Tekuteva, managing partner of the company Arnika Bio.
According to Elena Kharisova, Director General of the ISTC Development Fund, biotechnology is one of the key areas for the center’s development. “Residents are working on solutions that have clear practical application and are focused on real needs. It is important that technologies are not abstract developments, but tools that improve the quality of life and find application in the economy and social sphere,” she emphasized.
It is expected that by 2030, the first 16 residents of the ISTC’s pilot site will develop at least 100 technologies. By 2036, four scientific and educational clusters will appear on Russky Island: “IT Park,” “Biotechnology,” “Marine Engineering,” and “Biomedicine,” which will unite more than 250 companies, and the products they produce will reach the markets of Russia and the Asia-Pacific region.
As previously reported, pharmaceutical companies became the first residents of the innovation center on Russky Island, launched in September. One of them — Avexima Innotech — intends to develop domestic versions of four critically important drugs for the treatment of cancer, heart diseases, and diabetes.
